330 related articles for article (PubMed ID: 36291152)
1. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia.
Muñoz J; Paludo J; Sarosiek S; Castillo JJ
Cells; 2022 Oct; 11(20):. PubMed ID: 36291152
[TBL] [Abstract][Full Text] [Related]
2. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
[TBL] [Abstract][Full Text] [Related]
3. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J; Wang Y; Jain P; Wang M
Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
[TBL] [Abstract][Full Text] [Related]
4. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
5. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
[TBL] [Abstract][Full Text] [Related]
6. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Argyropoulos KV; Palomba ML
Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
[TBL] [Abstract][Full Text] [Related]
7. Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.
Deshpande A; Munoz J
Ther Clin Risk Manag; 2022; 18():657-668. PubMed ID: 35770040
[TBL] [Abstract][Full Text] [Related]
8. Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review.
Moore DC
J Oncol Pharm Pract; 2021 Dec; 27(8):1993-1999. PubMed ID: 34558376
[TBL] [Abstract][Full Text] [Related]
9. Management of Waldenström macroglobulinemia in 2020.
Castillo JJ; Treon SP
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS; Ou YC; Trotman J; Opat S
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
[No Abstract] [Full Text] [Related]
11. BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.
Varettoni M; Matous JV
Hematol Oncol Clin North Am; 2023 Aug; 37(4):707-717. PubMed ID: 37246088
[TBL] [Abstract][Full Text] [Related]
12. Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with
Zhu J; Zhu X; Xie F; Ding Y; Lu H; Dong Y; Li P; Fu J; Liang A; Zeng Y; Xiu B
Pathol Oncol Res; 2023; 29():1611070. PubMed ID: 37151353
[No Abstract] [Full Text] [Related]
13. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Castillo JJ; Buske C; Trotman J; Sarosiek S; Treon SP
Am J Hematol; 2023 Feb; 98(2):338-347. PubMed ID: 36415104
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M
Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259
[TBL] [Abstract][Full Text] [Related]
15. Managing Waldenström's macroglobulinemia with BTK inhibitors.
Buske C; Jurczak W; Salem JE; Dimopoulos MA
Leukemia; 2023 Jan; 37(1):35-46. PubMed ID: 36402930
[TBL] [Abstract][Full Text] [Related]
16. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
[TBL] [Abstract][Full Text] [Related]
17. Optimizing BTK Inhibition in Waldenström Macroglobulinemia.
Sarosiek S; Castillo JJ
J Natl Compr Canc Netw; 2024 May; 22(4):. PubMed ID: 38754469
[TBL] [Abstract][Full Text] [Related]
18. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
[TBL] [Abstract][Full Text] [Related]
19. What is new in the treatment of Waldenstrom macroglobulinemia?
Castillo JJ; Treon SP
Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468
[TBL] [Abstract][Full Text] [Related]
20. Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage.
Sarosiek S; Castillo JJ
Drugs; 2024 Jan; 84(1):17-25. PubMed ID: 38055179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]